Amgen rises 5.91% as higher guidance narrows remaining earnings test
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Amgen (NASDAQ:AMGN) gave investors a reason to pay up. The biotechnology company raised its full-year outlook after Tuesday's close, and shares climbed 5.91% to $488.50 at 8:28 a.m. ET in November 4 premarket trading. The stronger…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised guidance from a large biotech company can lift the stock in premarket trading.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Amgen raised its full-year outlook after Tuesday's close.
- 02Shares climbed 5.91% to $488.50 in premarket trading.
- 03Third-quarter revenue rose 8% to $10.4 billion.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets